Peter,
Thanks for Ambient and Sonata numbers.
I never have deep look on zopiclone. This is +15 years EU market drug. Any idea why drug isn’t on US market?
One more thing, zopiclone have stereoselective pharmacokinetics (each enatiomer metabolize at different rate). In regards that (-)-zopiclone is anti-anxiolytic (which should be positive for insomnia therapy) what are chance, in your view, that (+)-zopiclone (as enantiomer who stay longer in blood) will not potentate side effects (hangover for instance) and at the some time miss (-)-zopiclone good property.
Regards the +25 PII NBI trials I have hypothetical explanation.
Insomnia isn’t disease and symptoms have many different causes: medication use, emotional stress, anxiety and depression, fear and nervousness,… . So, NBIX decided that testing drug in more than several specific situations, different pts population (ages), drug-drug interactions, acute and chronic dosing, as well as further studies of the different doses (pharmacokinetic) is good why to get more data on drug potential and how to progress with pivotal trials (if at all). I do not have problems with this approach as long as main course is on track.
Miljenko |
